{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:13:35Z","timestamp":1790806415493,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Intestinal Beh\u00e7et's disease is a rare but severe manifestation of Beh\u00e7et's disease, particularly in pediatric populations. Currently, there is no cure for intestinal Beh\u00e7et's disease, and the goal of treatment is to control acute episodes and reduce inflammation. Adalimumab, a tumor necrosis factor-alpha (TNF-\u03b1) inhibitor, has shown promise in adult patients, but data on its efficacy and safety in children are limited. The aim of this study was to evaluate the efficacy and safety of adalimumab in the treatment of intestinal Beh\u00e7et's disease in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on 8 children with intestinal Beh\u00e7et's disease treated with adalimumab at Xi'an Children's Hospital from January 2021 to December 2024. Clinical symptoms, endoscopic findings, and inflammatory markers were assessed before and after treatment. Efficacy was evaluated on the basis of symptom resolution, ulcer healing, and changes in inflammatory markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort included 4 males and 4 females, with an average age of 11.9\u2009\u00b1\u20091.4 years and a disease course of 10.5 (6.75, 22.5) months. All patients presented with gastrointestinal symptoms, including abdominal pain (<jats:italic>n<\/jats:italic>\u2009=\u20097), vomiting (<jats:italic>n<\/jats:italic>\u2009=\u20091), and complications such as intestinal obstruction (<jats:italic>n<\/jats:italic>\u2009=\u20093) and perforation (<jats:italic>n<\/jats:italic>\u2009=\u20091). Colonoscopy revealed ileocecal ulcers in 7 patients and only terminal ileal ulcers in 1 patient. After treatment with adalimumab, complete resolution of clinical symptoms was observed in all patients. Gastrointestinal endoscopy revealed that 6 patients had completely healed ulcers, while the remaining 2 patients had ulcers that were reduced to 50% of their original size. The levels of inflammatory markers significantly decreased, with the erythrocyte sedimentation rate (ESR) decreasing from 44.63\u2009\u00b1\u200943.48\u2005mm\/h to 10.50\u2009\u00b1\u20097.65\u2005mm\/h (<jats:italic>p<\/jats:italic>\u2009=\u20090.046) and the high sensitivity C-reactive protein (hs-CRP) level decreasing from 43.87\u2009\u00b1\u200939.10\u2005mg\/L to 0.96\u2009\u00b1\u20090.67\u2005mg\/L (<jats:italic>p<\/jats:italic>\u2009=\u20090.017). On the basis of clinical symptoms and endoscopic findings, 6 patients (75%) achieved complete remission, and 2 patients (25%) showed improvement. Adalimumab was well tolerated, with only one case of mild eczema reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab is safe and effective in the treatment of intestinal Beh\u00e7et's disease in children.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1619065","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:26:14Z","timestamp":1751261174000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic effect of adalimumab in the treatment of intestinal Beh\u00e7et's disease in children"],"prefix":"10.3389","volume":"13","author":[{"given":"Tianjiao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengfan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/bor.0000000000001057","article-title":"Juvenile Beh\u00e7et syndrome: a contemporary view and differential diagnosis in pediatric practice","volume":"37","author":"Yildiz","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.46497\/ArchRheumatol.2024.11049","article-title":"New and future perspectives in Beh\u00e7et\u2019s syndrome","volume":"39","author":"Sulu","year":"2024","journal-title":"Arch Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.disamonth.2023.101674","article-title":"Gastrointestinal Beh\u00e7et\u2019s disease: manifestations, diagnosis, and management","volume":"70","author":"Manuelyan","year":"2024","journal-title":"Dis Mon"},{"key":"B4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s13256-023-04148-w","article-title":"Beh\u00e7et\u2019s disease with intestinal involvement: a case report and review of the literature","volume":"17","author":"Li","year":"2023","journal-title":"J Med Case Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17562848231167283","DOI":"10.1177\/17562848231167283","article-title":"The treatment principles and targets for intestinal Behcet\u2019s disease","volume":"16","author":"He","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1483993","DOI":"10.3389\/fimmu.2024.1483993","article-title":"Case report: successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Beh\u00e7et\u2019s disease","volume":"15","author":"Sha","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00417-015-3016-0","article-title":"Serum omentin, resistin and tumour necrosis factor-\u03b1 levels in Behcet patients with and without ocular involvement","volume":"253","author":"T\u00fcrkc\u00fc","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/03009740701747137","article-title":"Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Beh\u00e7et\u2019s disease","volume":"37","author":"Turan","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12876-023-03090-x","article-title":"Effectiveness and safety of adalimumab in patients with intestinal Beh\u00e7et\u2019s disease: a real-world prospective observational study in South Korea","volume":"23","author":"Yu","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","article-title":"Long-term safety and efficacy of Adalimumab for intestinal Beh\u00e7et\u2019s disease in the open label study following a phase 3 clinical trial","volume":"15","author":"Inoue","year":"2017","journal-title":"Intest Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B12","first-page":"187","article-title":"Diagnosis of intestinal Beh\u00e7et\u2019s disease","volume":"53","author":"Cheon","year":"2009","journal-title":"Korean J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.5009\/gnl220278","article-title":"Efficacy and safety of infliximab in intestinal Beh\u00e7et\u2019s disease: a multicenter, phase 3 study (BEGIN)","volume":"17","author":"Cheon","year":"2023","journal-title":"Gut Liver"},{"key":"B15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/mr\/roab127","article-title":"Predictors of infliximab refractory intestinal Beh\u00e7et\u2019s syndrome: a retrospective cohort study from the Shanghai Beh\u00e7et\u2019s syndrome database","volume":"33","author":"Bao","year":"2023","journal-title":"Mod Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00296-019-04300-0","article-title":"Adalimumab In the treatment of pediatric Beh\u00e7et\u2019s disease: case-based review","volume":"39","author":"Poddighe","year":"2019","journal-title":"Rheumatol Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40259-023-00613-6","article-title":"Treatment with biologic drugs in pediatric Beh\u00e7et\u2019s disease: a comprehensive analysis of the published data","volume":"37","author":"Batu","year":"2023","journal-title":"BioDrugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109242","DOI":"10.1016\/j.clim.2023.109242","article-title":"Long-term data on efficacy and safety of Adalimumab in Beh\u00e7et\u2019s disease","volume":"247","author":"van der Houwen","year":"2023","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1619065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:26:15Z","timestamp":1751261175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1619065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":18,"alternative-id":["10.3389\/fped.2025.1619065"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1619065","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1619065"}}